Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bracco gets rights to phage display technology:

This article was originally published in Clinica

Executive Summary

Milan, Italy-based Bracco will pay $3 million for a worldwide exclusive licence to Dyax's proprietary phage display technology to develop imaging products. Bracco will pay Cambridge, Massachusetts-based Dyax a further $3 million per year in funding over the next three to six years, as well as development milestones and royalties. Phase display is a discovery method to identify proteins, peptides and human monoclonal antibodies that bind to diagnostic and therapeutic targets. The agreement covers the right to develop and commercialise existing Dyax product leads in inflammation, cardiovascular and oncology imaging.

Advertisement
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT075212

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel